What Does AERS Mean? FDA Takes A Close Look At Spontaneous Reporting
Executive Summary
Amid a flurry of recent drug safety initiatives, FDA is not losing sight of the importance of spontaneous adverse event reporting. In fact, the agency is taking steps to evaluate and improve its passive surveillance system, which it expects to remain the cornerstone of its drug safety oversight
You may also be interested in...
FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
FDA’s 5-Year Plan For User Fees Puts Post- And Pre-Market On Equal Footing
Over the next five years, FDA will shift its regulatory focus to ensure that the safe and effective use of drugs is of equal importance as ushering safe and effective medicines to market
Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects